Posted by Michael Wonder on 11 Mar 2021
FDA grants breakthrough device designation for Inivata’s RaDaR assay
9 March 2021 - Designation will help accelerate the regulatory path of RaDaR for use in detection of minimal residual disease in early stage cancer patients
Inivata today announces that the U.S. FDA has granted breakthrough device designation for its RaDaR assay.
